KDR and neoplasm: In addition, circulating VEGFR variants, circulating endothelial cells (CECs), and circulating tumor cells (CTCs) hold promise as biomarkers for assessing treatment response, reinforcing the need for biomarker-driven precision medicine strategies in PC.